BR112015007126A2 - composição, método para induzir uma resposta imune, e, uso de uma composição - Google Patents
composição, método para induzir uma resposta imune, e, uso de uma composiçãoInfo
- Publication number
- BR112015007126A2 BR112015007126A2 BR112015007126A BR112015007126A BR112015007126A2 BR 112015007126 A2 BR112015007126 A2 BR 112015007126A2 BR 112015007126 A BR112015007126 A BR 112015007126A BR 112015007126 A BR112015007126 A BR 112015007126A BR 112015007126 A2 BR112015007126 A2 BR 112015007126A2
- Authority
- BR
- Brazil
- Prior art keywords
- conjugates
- composition
- immune response
- saccharide
- linear
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1 / 1 resumo âcomposiãão, mãtodo para induzir uma resposta imune, e, uso de uma composiããoâ este relatã³rio descritivo ã© direcionado aos conjugados de sacarãdeo nã£o lineares que compreendem polissacarãdeos que sã£o ligados a pelo menos dois peptãdeos que compreendem epãtopos de cã©lula t e nã£o tãªm nenhum dos epãtopos de cã©lula b conformacionais onde um dos peptãdeos ã© ligado a um sacarãdeo interno de modo que os conjugados tenham uma estrutura ramificada (isto ã©, nã£o linear). o relatã³rio descritivo tambã©m fornece mã©todos de fabricaã§ã£o destes conjugados, mã©todos de formulaã§ã£o destes conjugados em composiã§ãµes para o uso como vacinas e mã©todos para usar as composiã§ãµes para induzir uma resposta imune ao sacarãdeo capsular. o relatã³rio descritivo tambã©m fornece um novo peptãdeo carreador de poliepãtopo compreendendo o epãtopo pv1 do vãrus da poliomielite. o novo peptãdeo carreador de poliepãtopo pode ser usado tanto em conjugados de sacarãdeo lineares assim como nos conjugados de sacarãdeo nã£o lineares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261709093P | 2012-10-02 | 2012-10-02 | |
PCT/EP2013/070496 WO2014053521A2 (en) | 2012-10-02 | 2013-10-02 | Nonlinear saccharide conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015007126A2 true BR112015007126A2 (pt) | 2017-08-08 |
Family
ID=49293654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015007126A BR112015007126A2 (pt) | 2012-10-02 | 2013-10-02 | composição, método para induzir uma resposta imune, e, uso de uma composição |
Country Status (15)
Country | Link |
---|---|
US (1) | US20160101187A1 (pt) |
EP (1) | EP2903650B1 (pt) |
JP (1) | JP2015532276A (pt) |
KR (1) | KR20150060986A (pt) |
CN (1) | CN105307684A (pt) |
AU (1) | AU2013326584B2 (pt) |
BR (1) | BR112015007126A2 (pt) |
CA (1) | CA2885625A1 (pt) |
EA (1) | EA201590427A1 (pt) |
ES (1) | ES2672996T3 (pt) |
IL (1) | IL237826A0 (pt) |
MX (1) | MX2015004171A (pt) |
SG (1) | SG11201502197XA (pt) |
TR (1) | TR201808684T4 (pt) |
WO (1) | WO2014053521A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104072765B (zh) * | 2014-07-09 | 2017-07-28 | 中国科学院长春应用化学研究所 | 改性聚乙烯亚胺及其制备方法、药物‑基因载体系统及其制备方法 |
IL255106B2 (en) | 2015-05-04 | 2023-04-01 | Pfizer | Protein-polysaccharide conjugates of group b streptococcus, methods for preparing conjugates, immunogenic preparations containing conjugates and their uses |
SG11201901394XA (en) | 2016-09-02 | 2019-03-28 | Sanofi Pasteur Inc | Neisseria meningitidis vaccine |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
MD20190088A2 (ro) * | 2017-05-05 | 2020-04-30 | Serum Institute Of India Private Limited | Metodă de eliminare a impurităţilor din preparatele pe bază de polizaharide capsulare bacteriene |
WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
WO2020010000A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Improved methods for the preparation of immunogenic conjugates |
BR112020026899A2 (pt) | 2018-07-04 | 2021-03-30 | Vaxcyte, Inc. | Melhorias em conjugados imunogênicos |
JP7257021B2 (ja) * | 2018-09-03 | 2023-04-13 | 公立大学法人大阪 | 免疫賦活性乳化剤 |
CN113812409B (zh) * | 2021-11-24 | 2022-03-01 | 山东科大创业生物有限公司 | 防治植物白粉病组合物及其制备方法、应用 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
US4680338A (en) | 1985-10-17 | 1987-07-14 | Immunomedics, Inc. | Bifunctional linker |
US5011828A (en) | 1985-11-15 | 1991-04-30 | Michael Goodman | Immunostimulating guanine derivatives, compositions and methods |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US5204098A (en) | 1988-02-16 | 1993-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-protein conjugates |
NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
JPH04500203A (ja) | 1988-08-25 | 1992-01-16 | ザ リポソーム カンパニー,インコーポレイテッド | インフルエンザワクチンおよび新規なアジュバント |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
US4988815A (en) | 1989-10-26 | 1991-01-29 | Riker Laboratories, Inc. | 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines |
US5658731A (en) | 1990-04-09 | 1997-08-19 | Europaisches Laboratorium Fur Molekularbiologie | 2'-O-alkylnucleotides as well as polymers which contain such nucleotides |
US5153312A (en) | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
HU222247B1 (hu) | 1991-03-01 | 2003-05-28 | Minnesota Mining And Manufacturing Company | 1- és 2-helyzetben szubsztituált 1H-imidazo[4,5-c]kinolin-4-amin-származékok előállításában alkalmazható 1H-imidazo[4,5-c]kinolin-5N-oxid-származékok |
EP0761231B1 (en) | 1992-06-25 | 2000-01-12 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Vaccine composition containing adjuvants |
DK0689454T4 (da) | 1993-03-23 | 2005-05-30 | Smithkline Beecham Biolog | Vaccinepræparater indeholdende 3-O-deacyleret monophosphoryl-lipid A |
WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
JP2000511769A (ja) | 1996-04-02 | 2000-09-12 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
WO1997043303A1 (en) | 1996-05-14 | 1997-11-20 | Smithkline Beecham Corporation | Novel compounds |
WO1998018930A2 (en) | 1996-10-31 | 1998-05-07 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
US6818222B1 (en) | 1997-03-21 | 2004-11-16 | Chiron Corporation | Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
PT969873E (pt) * | 1997-03-27 | 2006-09-29 | Pasteur Institut | Hidrato de carbono glicopeptido antigene multiplo, vacina abrangendo o mesmo e seu uso |
US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
ES2201551T3 (es) | 1997-09-05 | 2004-03-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
KR100585408B1 (ko) | 1998-02-12 | 2006-06-01 | 와이어쓰 홀딩스 코포레이션 | 인터루킨-12로 제형된 폐렴구균 및 수막구균 백신 |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
IL138000A0 (en) | 1998-04-09 | 2001-10-31 | Smithkline Beecham Biolog | Adjuvant compositions |
GB9808932D0 (en) * | 1998-04-27 | 1998-06-24 | Chiron Spa | Polyepitope carrier protein |
DK1075276T3 (da) | 1998-05-07 | 2008-02-11 | Corixa Corp | Adjuvanssammensætning og fremgangsmåder til dens anvendelse |
DE19821859A1 (de) * | 1998-05-15 | 1999-12-09 | M Alexander Schmidt | Darstellung immunogener (Kapsel-)Polysaccharid-Konjugate durch orientierte Kupplung synthetischer T-Zell-Epitope zur Erzeugung von Vakzinen gegen N.meningitidis |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
KR100704826B1 (ko) | 1998-08-19 | 2007-04-09 | 박스터 헬쓰케어 에스.에이. | N-아크릴로일화된 폴리사카라이드를 사용하여 제조된백신으로서 사용하기에 적합한 면역원성β-프로피온아미도-결합 폴리사카라이드 단백질 컨쥬게이트 |
DE122007000087I1 (de) | 1998-10-16 | 2008-03-27 | Glaxosmithkline Biolog Sa | Adjuvanzsysteme und impfstoffe |
US6146902A (en) | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
IL144084A0 (en) | 1999-02-03 | 2002-05-23 | Biosante Pharmaceuticals Inc | Therapeutic calcium phosphate particles and methods of manufacture and use |
HUP0203817A3 (en) | 1999-09-24 | 2004-07-28 | Smithkline Beecham Biolog | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
CZ20021043A3 (cs) | 1999-09-24 | 2002-08-14 | Smithkline Beecham Biologicals S. A. | Pouľití kombinace polyoxyethylensorbitanového esteru a oktoxynolu pro výrobu pomocného prostředku |
TR200200797T2 (tr) | 1999-09-25 | 2002-10-21 | University Of Iowa Research Foundation | İmmünostimülatör nükleik asitler |
WO2001095935A1 (en) | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
EP1313734B1 (en) | 2000-09-01 | 2009-11-11 | Novartis Vaccines and Diagnostics, Inc. | Aza heterocyclic derivatives and their therapeutic use |
AP1666A (en) | 2000-09-11 | 2006-09-29 | Chiron Corp | Quinolinone derivatives as tyrosine kinase inhibitors. |
KR100865706B1 (ko) | 2000-09-26 | 2008-10-28 | 이데라 파마슈티칼즈, 인코포레이티드 | 화학적인 위치 변화에 의해 면역자극 올리고누클레오티드유사체의 면역자극 활성을 조절하는 방법 |
NZ583028A (en) | 2000-10-27 | 2011-10-28 | Novartis Vaccines & Diagnostic | Nucleic acids and proteins from streptococcus groups A & B |
WO2002081653A2 (en) | 2001-04-03 | 2002-10-17 | Biosynexus Incorporated | An animal model for enteric pathogens |
US20030099668A1 (en) | 2001-09-14 | 2003-05-29 | Cytos Biotechnology Ag | Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
ATE448238T1 (de) | 2001-11-27 | 2009-11-15 | Anadys Pharmaceuticals Inc | 3-beta-d-ribofuranosylthiazolo(4,5- delta)pyridimin-nucleoside und ihre verwendung |
ES2336094T3 (es) | 2002-03-29 | 2010-04-08 | Novartis Vaccines And Diagnostics, Inc. | Benzazoles sustituidos y uso de los mismos como inhibidores de quinasa raf. |
GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
WO2003105769A2 (en) | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
ATE477251T1 (de) | 2002-08-23 | 2010-08-15 | Novartis Vaccines & Diagnostic | Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren |
PT1551357E (pt) | 2002-09-13 | 2014-10-10 | Novartis Vaccines & Diagnostic | Vacina contra os estreptococos do grupo b |
AU2003275954A1 (en) * | 2002-11-08 | 2004-06-07 | Danmarks Fodevareforskning | Preparation of chemically well-defined carbohydrate dendrimer conjugates |
US7521062B2 (en) | 2002-12-27 | 2009-04-21 | Novartis Vaccines & Diagnostics, Inc. | Thiosemicarbazones as anti-virals and immunopotentiators |
ES2391770T3 (es) | 2003-01-21 | 2012-11-29 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos de triptantrina para la potenciación inmune |
GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
ES2423800T3 (es) | 2003-03-28 | 2013-09-24 | Novartis Vaccines And Diagnostics, Inc. | Uso de compuestos orgánicos para la inmunopotenciación |
WO2005002619A2 (en) | 2003-06-26 | 2005-01-13 | Chiron Corporation | Immunogenic compositions for chlamydia trachomatis |
RU2236257C1 (ru) | 2003-09-15 | 2004-09-20 | Косяков Константин Сергеевич | Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами |
WO2005097181A1 (en) | 2004-04-05 | 2005-10-20 | Pfizer Products Inc. | Microfluidized oil-in-water emulsions and vaccine compositions |
GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
BRPI0612669B8 (pt) | 2005-06-27 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, vacina, composição, e composição liofilizada |
US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
PT2227248E (pt) | 2007-11-26 | 2014-08-27 | Novartis Ag | Glucanos com adjuvante |
ES2812523T3 (es) * | 2009-09-30 | 2021-03-17 | Glaxosmithkline Biologicals Sa | Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8 |
CN103108654A (zh) * | 2010-06-11 | 2013-05-15 | 索隆-基特林癌症研究协会 | 多价糖肽构建体及其用途 |
-
2013
- 2013-10-02 BR BR112015007126A patent/BR112015007126A2/pt active Search and Examination
- 2013-10-02 US US14/432,848 patent/US20160101187A1/en not_active Abandoned
- 2013-10-02 SG SG11201502197XA patent/SG11201502197XA/en unknown
- 2013-10-02 AU AU2013326584A patent/AU2013326584B2/en not_active Ceased
- 2013-10-02 KR KR1020157011597A patent/KR20150060986A/ko not_active Application Discontinuation
- 2013-10-02 EA EA201590427A patent/EA201590427A1/ru unknown
- 2013-10-02 ES ES13771153.7T patent/ES2672996T3/es active Active
- 2013-10-02 EP EP13771153.7A patent/EP2903650B1/en active Active
- 2013-10-02 TR TR2018/08684T patent/TR201808684T4/tr unknown
- 2013-10-02 CA CA2885625A patent/CA2885625A1/en not_active Abandoned
- 2013-10-02 WO PCT/EP2013/070496 patent/WO2014053521A2/en active Application Filing
- 2013-10-02 JP JP2015533636A patent/JP2015532276A/ja active Pending
- 2013-10-02 CN CN201380062942.6A patent/CN105307684A/zh active Pending
- 2013-10-02 MX MX2015004171A patent/MX2015004171A/es unknown
-
2015
- 2015-03-19 IL IL237826A patent/IL237826A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20160101187A1 (en) | 2016-04-14 |
CA2885625A1 (en) | 2014-04-10 |
MX2015004171A (es) | 2015-10-22 |
EA201590427A1 (ru) | 2015-09-30 |
IL237826A0 (en) | 2015-05-31 |
WO2014053521A3 (en) | 2014-07-17 |
TR201808684T4 (tr) | 2018-07-23 |
EP2903650B1 (en) | 2018-04-04 |
CN105307684A (zh) | 2016-02-03 |
AU2013326584B2 (en) | 2016-12-01 |
JP2015532276A (ja) | 2015-11-09 |
SG11201502197XA (en) | 2015-04-29 |
KR20150060986A (ko) | 2015-06-03 |
EP2903650A2 (en) | 2015-08-12 |
WO2014053521A2 (en) | 2014-04-10 |
ES2672996T3 (es) | 2018-06-19 |
AU2013326584A1 (en) | 2015-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015007126A2 (pt) | composição, método para induzir uma resposta imune, e, uso de uma composição | |
CL2018000515A1 (es) | Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015) | |
BR112015011447A2 (pt) | composto da fórmula i, composição farmacêutica e de vacina, e, uso de um composto | |
BR112018011122A2 (pt) | antígenos, vetores, composições, e métodos de utilização para o vírus da imunodeficiência humana dos mesmos | |
BR112017012344A2 (pt) | anticorpos anti-c10orf54 e usos dos mesmos | |
MX2013013111A (es) | Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma. | |
NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
CL2018001159A1 (es) | Vacuna para adenovirus aviar (divisional de solicitud n° 358-2016) | |
BR112012004806B8 (pt) | composições imunogênicas que incluem moduladores da atividade de tlr, método para aumento da eficácia da referida composição e uso | |
BR112015006605A2 (pt) | vacina atenuada viva, método de produzir um arterivírus, arterivírus, e, complexo plp2-ubiquitina ou complexo plp2-isg15 | |
BR112015023142A8 (pt) | moduladores do p2x7,seu uso, processo de preparação e composição farmacêutico que os compreende | |
MX2016003419A (es) | Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico. | |
BR112013002940A2 (pt) | adjuvantes de nova vacina baseados no direcionamento dos adjuvantes para os anticorpos diretamente às células que apresentam antígenos | |
BR112014018815A8 (pt) | Composição imunogênica compreendendo conjugado proteína-polissacarídeo x de n. meningitidis | |
CL2015001900A1 (es) | Vacunas con mayor densidad de antigeno carbohidrato y nuevo adyuvante de saponina. | |
NZ630831A (en) | Compositions and methods for administration of vaccines against dengue virus | |
NZ630869A (en) | Compositions and methods for dengue virus chimeric constructs in vaccines | |
BR112014011560A2 (pt) | complexos imunogênicos de carbômeros polianiônicos e polipeptídeos env, e métodos de fabricação e uso dos mesmos | |
BR112016004108A2 (pt) | métodos para expressar uma molécula antigênica ou uma parte da mesma e para geração de uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e de uma molécula antigênica, moléculas antigênica, agentes de fotossensibilização e ligante tlr e agente, produto, e, kit | |
BR112014027620A2 (pt) | formulação, uso de uma formulação, processo para fabricar uma formulação, composto, e, processo para a preparação de um composto | |
MX2015007753A (es) | Composicion de vacunas para sujetos intactos. | |
BR112012016048A2 (pt) | "exossomas derivados de reticulócitos infectados com plasmodium sp., método para obter os mesmos e usos dos mesmos". | |
BR112018068342A2 (pt) | vacina de vírus zika vivo atenuado | |
BR112017015288A2 (pt) | vacina contra febre aftosa | |
CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), A61K 39/095 (2006.01), A61P |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2534 DE 30-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |